iSpecimen Business Summary

iSpecimen Inc. (ISPC) operates a proprietary, technology-enabled marketplace that streamlines the procurement of human biospecimens for medical research. The company generates revenue primarily through transaction-based specimen contracts, facilitating the sale of biofluids, tissues, and cells from a global network of healthcare providers to researchers in the pharmaceutical, biotechnology, and academic sectors. A secondary revenue stream is derived from logistics, shipping, and processing services. As of February 2026, the company has completed the second milestone of its "SalesStack" digital transformation, integrating AI-assisted matching to automate supplier inventories. iSpecimen positions itself as a niche, asset-light intermediary in the biospecimen contract research market, competing directly with firms such as Inotiv (NOTV), Samfine Creation Holdings Group (SFHG), and Avalon (AWX) by replacing manual biobanking with a searchable, two-sided digital platform. iSpecimen was founded in 2009 by a team of pathologists led by Dr. Christopher Ianelli, who served as CEO until 2022. The current leadership team is headed by Katharyn "Katie" Field, who serves as CEO, President, Secretary, and Treasurer following a strategic executive transition in late 2025. Field holds a pedigree that includes an MBA from Columbia Business School, a BA from Stanford University, and professional tenures at Bain & Company and The Brookings Institution. The company's governance is overseen by a board that includes Anthony Lau (Audit Chair), Avtar Dhaliwal, and Siyun Yang. Despite recent market volatility and a pivot toward a $200 million Solana-based digital treasury strategy, iSpecimen maintains institutional interest from notable investors such as Renaissance Technologies, Virtu Financial, and Geode Capital Management.